Canopy Growth Corp
TSX:WEED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (3.2), the stock would be worth CA$2.68 (67% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.9 | CA$1.61 |
0%
|
| 3-Year Average | 3.2 | CA$2.68 |
+67%
|
| 5-Year Average | 21.2 | CA$17.69 |
+999%
|
| Industry Average | 1.5 | CA$1.21 |
-25%
|
| Country Average | 2.9 | CA$2.43 |
+51%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
CA$471.2m
|
/ |
Jan 2026
CA$278.4m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2026
CA$291.2m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2027
CA$336.9m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2028
CA$363.8m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2029
CA$427.4m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2030
CA$465.7m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2031
CA$506.6m
|
= |
|
|
CA$471.2m
|
/ |
Mar 2032
CA$548.1m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Canopy Growth Corp
TSX:WEED
|
752.2m CAD | 1.9 | -1.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 13.3 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.2 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.2 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 4.8 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 4.1 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 3.2 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 3.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 2.9 |
| 70th Percentile | 5.7 |
| Max | 15 639 353.3 |
Other Multiples
Canopy Growth Corp
Glance View
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company is headquartered in Smiths Falls, Ontario and currently employs 3,259 full-time employees. The company went IPO on 2010-06-04. The firm operates through two segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment comprises the production, distribution and sale of consumer products, including Storz & Bickel vaporizers; This Works beauty, skincare, wellness and sleep products; BioSteel sports nutrition beverages, mixes, protein, gum and mints; and other revenue sources.
